Clinical Trial Detail

NCT ID NCT03279250
Title Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

prostate adenocarcinoma

Therapies

Goserelin

Triptorelin

Abiraterone + Apalutamide + Prednisone

Leuprolide

Apalutamide

Age Groups: adult senior

No variant requirements are available.